Octreotide Acetate — 500MCG/2ML, Solution for injection, carton of 10 × 1 mL vials

Octreotide Acetate — 500MCG/2ML, Solution for injection, carton of 10 × 1 mL vials

Octreotide Acetate is a solution for injection for intravenous; subcutaneous use. Octreotide acetate injection is a somatostatin analogue indicated: Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors: For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas): For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with octreotide acetate injection;

• Active ingredient or product type: OCTREOTIDE ACETATE
• Strength/concentration: 500MCG/2ML
• Dosage form and route: Solution for injection, Intravenous; Subcutaneous
• Exact package presentation: carton of 10 × 1 mL vials
• NDC/item number: 0641-6176-10
• Manufacturer: HIKMA PHARMACEUTICALS USA INC
• Storage/handling: stored at refrigerated temperatures 2°C to 8°C (36°F to 46°F) and store in outer carton in order to protect from light.
• Status: Rx only

Important safety information: Cardiac Function Abnormalities: Increased risk for higher degree of atrioventricular blocks.

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.